Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026
But the weight loss and metabolic changes it produces can restart ovulation in women who werent ovulating regularly, including those with PMOS
Flushing was described as the reason for discontinuing therapy for 6% of patients receiving Niaspan in pivotal studies
HGH initiates a complex cascade of hormonal events that ultimately promote growth and tissue repair, with IGF-1 serving as its most anabolic downstream mediator. Molitch, M
To overcome these difficulties, scientists are trying to use bee products in nanotechnology, which are safe, effective, and target-specific
